Trends in antihypertensive prescribing

New Zealand Medical Journal

Volumn 109, Issue 1014, 1996, Pages 4-7

  Penrose, Auster ^a   Dovey, Susan ^a   Tilyard, Murray ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; COMPUTER; DATA ANALYSIS; DRUG COST; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PRESCRIPTION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DRUG COSTS; DRUG UTILIZATION; FEMALE; HEALTH EXPENDITURES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG;

EID: 0030062256     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Sutton F. Trends in pharmaceutical benefit expenditure over the last decade. Wellington: Department of Health, 1988.
2. Ferguson RI, Maling TJB. The Nelson general practice prescribing project. Part 1: a pilot audit of the regional prescribing profile. NZ Med J 1990; 103: 559.
3. National Advisory Committee on Core Health & Disability Services The management of raised blood pressure in New Zealand: A consensus development conference report to the National Advisory Committee on Core Health and Disability Services. Wellington: National Advisory Committee on Core Health and Disability Services, 1992.
4. Knorr M, Frielingsdorf J, Graf F, et al. Prescription patterns and cost of antihypertensive drugs in two outpatient clinics: Zurich (Switzerland) and Munster (FRG). Nephron 1987; 47(Suppl 1): 120-4.
5. Gilley J. Towards rational prescribing: better prescribing takes time. BMJ 1994; 308: 731-2.
6. Bond C, Taylor R. Change in the established prescribing habits of general practitioners: An analysis of initial prescriptions in general practice. Br J Gen Pract 1991; 41: 244-8.
7. Williams A. Creating a healthcare market: ideology, efficiency, ethics and clinical freedom. University of York Centre for Health Economics, 1989: 14.
8. Williams A. The role of health economics in clinical decision making: is it ethical? Respir Med 1991; 85 (Suppl. B): 3-5.
9. Adis International. New Ethicals Catalogue. August 1991;28(2).
10. Adis International. New Ethicals Catalogue. August 1992;29(2).
11. Adis International. New Ethicals Catalogue. August 1993;30(2).
12. Statistics New Zealand. Key statistics June 1994. Wellington: Statistics New Zealand, 1994.
13. Nilsson P, Kandell-Collen A, Lindholm LH, et al. Care of hypertensives in Dalby: organisation and health economic aspects J Hum Hypertens 1993; 7: 551-4.
14. National Advisory Committee on Core Health & Disability Services. Core health & disability support services for 1993/94. Wellington: New Zealand, 1992.
15. Tilyard MW, Dovey SM, Spears GFS. Biases in estimates from the RNZCGP Computer Research Group. N Z Med J 1995; in press.
16. Sinclair LB, Ashton T, Jackson R, et al. Trends in antihypertensive medication costs in a cohort of Aucklanders 1982-87. N Z Med J 1989;102:521-3.
17. Bogle SM, Harris CM. Measuring prescribing: the shortcomings of the item. BMJ 1994; 308: 637-40.
18. Manolio TA, Jeffrey AC, Curt D et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995; 155: 829-37.